BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

South Korea

Lunit Reveals Positive Study Results for Head and Neck Cancer Immunotherapy

Lunit, a global leader in AI-driven cancer diagnostics and therapy solutions, is thrilled to share the publication of a groundbreaking study in the prestig...

March 27, 2024 | News

TiumBio Initiates Phase 1b Trial for New Hemophilia Treatment TU7710

TiumBio Co., Ltd., a trailblazer in the biopharmaceutical landscape, dedicated to crafting groundbreaking therapies for rare and untreatabl...

March 27, 2024 | News

DigmBio's Breakthrough Cancer Drug Clears Korean Regulatory Hurdle

BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breas...

March 26, 2024 | News

Oscotec Inc. Gains FDA Orphan Drug Designation for Promising ITP Treatment Cevidoplenib

Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immun...

March 22, 2024 | News

SK bioscience Breaks Ground in Southeast Asia and Southern Hemisphere with 440,000 Dose Vaccine Export to Thailand

Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. Company has obtained m...

March 21, 2024 | News

Merck Invests Over €300 Million in New Daejeon Bioprocessing Center, Elevating Asia-Pacific's Biologics Sector and Generating 300 Jobs

Site to supply products to customers for development and production of biologics New Bioprocessing Production Center in Daejeon strengthens footprint of...

March 20, 2024 | News

South Korean Lunit Forges Ahead in Europe with AI-Enhanced Cancer Detection

Lunit, a trailblazer in AI-driven diagnostics and cancer treatment, announced significant strides in its European market presence through new...

March 19, 2024 | News

Lunit's Bid to Acquire Volpara Gains Momentum with New Zealand High Court's Initial Nod

Volpara Health Technologies (Volpara; ASX:VHT), renowned for its AI-driven solutions in cancer diagnostics, is on the brink of a transformative merger with...

March 14, 2024 | News

TiumBio Advances TU2218 in Phase 2a Trial with Pembrolizumab for Three Cancer Types

TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab TU2218 demonstrated a favorable safety and a synerget...

March 12, 2024 | News

ImmunAbs Announces Triumph in Phase 1 Clinical Trial of Novel Autoimmune Disease Therapy, IM-101

ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of th...

March 12, 2024 | News

SK bioscience and Sanofi to Boost Global Vaccine Supply with Major Expansion of L HOUSE Manufacturing Plant

The company will expand its manufacturing plant, L HOUSE, with additional cGMP-level facility. The new space will serve as a production base for the pne...

March 08, 2024 | News

GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj

Immuncell-LC Inj. is an autologous Cytokine Induced Killer (CIK) cell therapy approved for Commercial use in South Korea as an adjuvant cell th...

February 27, 2024 | News

Enveric Biosciences Divests Cancer-Targeting Cannabinoid IP to Focus on Mental Health Therapeutics

Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology firm at the forefront of developing neuroplastogenic small-molecule therapeutics, an...

February 26, 2024 | News

Oscotec/ ADEL Launch First Human Trial for Novel Alzheimer's Treatment ADEL-Y01

In a significant stride towards Alzheimer's disease (AD) treatment, Oscotec Inc. in collaboration with ADEL Inc., has announced the initiation of f...

February 26, 2024 | News

Stay Connected